Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2013

Quidel Strep A Fluorescent Immunoassay Gets FDA OK

  • FDA this week awarded 510(k) clearance for Quidel’s Sofia Strep A fluorescent immunoassay (FIA) for the rapid detection of Group A Streptococcal infections.

    The company said that, when used with its next-generation immunoassay system, the Sofia Analyzer, this FIA test can produce an accurate diagnostic result within five minutes. Quidel is already using this system for flu testing. It added that Group A Streptococcus bacteria are the most common cause of bacterial pharyngitis, and can also cause rheumatic fever, among other illnesses.

    "We are confident that the Sofia Strep A FIA will provide customers with an easy-to-use, fast, and accurate solution for the diagnosis of Strep A infections, and will create added utilization for the Sofia platform beyond current influenza testing," Douglas Bryant, Quidel president and CEO, said in a statement.

    "In the short-term, the clearance of the Sofia Strep A FIA provides us with another catalyst for increasing Sofia placements in the field, and before the onset of the upcoming respiratory disease season,” Bryant added. “Over the long-term, our premium product addresses a market that, relative to influenza, represents a higher volume opportunity with less seasonality and less volatility."

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »